-
Something wrong with this record ?
Risk stratification using growth differentiation factor 15 in patients undergoing transcatheter aortic valve implantation
M. Sluka, M. Hutyra, R. Nykl, J. Ostransky, T. Furst, P. Petrova, J. Precek, S. Hudec, M. Taborsky
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
35416185
DOI
10.5507/bp.2022.017
Knihovny.cz E-resources
- MeSH
- Aortic Valve Stenosis * surgery MeSH
- Risk Assessment MeSH
- Humans MeSH
- Prospective Studies MeSH
- Risk Factors MeSH
- Growth Differentiation Factor 15 MeSH
- Aged, 80 and over MeSH
- Transcatheter Aortic Valve Replacement * adverse effects MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Aged, 80 and over MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
AIMS: Growth differentiation factor 15 (GDF15) shows potential predictive value in various cardiac conditions. We investigated relationships between GDF15 and clinical or procedural outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) in order to propose clinically useful predictive risk stratification model. METHODS: This prospective single-center registry enrolled 88 consecutive patients with severe symptomatic aortic stenosis treated with TAVI. Clinical parameters were collected and biomarkers including GDF-15 were measured within 24 h before TAVI. All relevant clinical outcomes according to the Valve Academic Research Consortium-2 were collected over the follow-up period. RESULTS: The cohort included 52.3% of females. The mean age of study participants was 81 years; the mean Society of Thoracic Surgeons (STS) score and logistic EuroSCORE were 3.6% and 15.4%, respectively. The mortality over the entire follow-up period was 10.2%; no death was observed within the first 30 days following TAVI. Univariate analysis showed significant associations between GDF15 and mortality (P=0.0006), bleeding (P=0.0416) and acute kidney injury (P=0.0399). A standard multivariate logistic regression model showed GDF-15 as the only significant predictor of mortality (P=0.003); the odds ratio corresponding to an increase in GDF15 of 1000 pg/mL was 1.22. However, incremental predictive value was not observed when the STS score was combined with GDF15 in this predictive model. CONCLUSIONS: Based on our observations, preprocedural elevated GDF15 levels are associated with increased mortality and demonstrate their additional value in predicting adverse clinical outcomes in a TAVI population.
Department of Clinical Biochemistry University Hospital Olomouc Czech Republic
Department of Internal Medicine 1 Cardiology University Hospital Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23018198
- 003
- CZ-PrNML
- 005
- 20231121092150.0
- 007
- ta
- 008
- 231107s2023 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2022.017 $2 doi
- 035 __
- $a (PubMed)35416185
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Sluka, Martin $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0114481
- 245 10
- $a Risk stratification using growth differentiation factor 15 in patients undergoing transcatheter aortic valve implantation / $c M. Sluka, M. Hutyra, R. Nykl, J. Ostransky, T. Furst, P. Petrova, J. Precek, S. Hudec, M. Taborsky
- 520 9_
- $a AIMS: Growth differentiation factor 15 (GDF15) shows potential predictive value in various cardiac conditions. We investigated relationships between GDF15 and clinical or procedural outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) in order to propose clinically useful predictive risk stratification model. METHODS: This prospective single-center registry enrolled 88 consecutive patients with severe symptomatic aortic stenosis treated with TAVI. Clinical parameters were collected and biomarkers including GDF-15 were measured within 24 h before TAVI. All relevant clinical outcomes according to the Valve Academic Research Consortium-2 were collected over the follow-up period. RESULTS: The cohort included 52.3% of females. The mean age of study participants was 81 years; the mean Society of Thoracic Surgeons (STS) score and logistic EuroSCORE were 3.6% and 15.4%, respectively. The mortality over the entire follow-up period was 10.2%; no death was observed within the first 30 days following TAVI. Univariate analysis showed significant associations between GDF15 and mortality (P=0.0006), bleeding (P=0.0416) and acute kidney injury (P=0.0399). A standard multivariate logistic regression model showed GDF-15 as the only significant predictor of mortality (P=0.003); the odds ratio corresponding to an increase in GDF15 of 1000 pg/mL was 1.22. However, incremental predictive value was not observed when the STS score was combined with GDF15 in this predictive model. CONCLUSIONS: Based on our observations, preprocedural elevated GDF15 levels are associated with increased mortality and demonstrate their additional value in predicting adverse clinical outcomes in a TAVI population.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 12
- $a transkatetrální implantace aortální chlopně $x škodlivé účinky $7 D065467
- 650 _2
- $a růstový diferenciační faktor 15 $7 D055436
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 12
- $a aortální stenóza $x chirurgie $7 D001024
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a prospektivní studie $7 D011446
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hutyra, Martin, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $d 1974- $7 xx0013232
- 700 1_
- $a Nykl, Radomír $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0227522
- 700 1_
- $a Ostransky, Jiri $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic
- 700 1_
- $a Furst, Tomas $u Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Petrová, Pavla $u Department of Clinical Biochemistry, University Hospital Olomouc, Czech Republic $7 xx0166833
- 700 1_
- $a Přeček, Jan, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $d 1985- $7 xx0154445
- 700 1_
- $a Hudec, Štěpán $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0227664
- 700 1_
- $a Táborský, Miloš, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $d 1962- $7 jn20010310074
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 3 (2023), s. 263-271
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35416185 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20231107 $b ABA008
- 991 __
- $a 20231121092147 $b ABA008
- 999 __
- $a ok $b bmc $g 2011499 $s 1204601
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 167 $c 3 $d 263-271 $e 20220412 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK198 $a Pubmed-20231107